Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | BTK | Q06187 | 8/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 3/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031427 | 0.87 | ESR1 (0.65) | ESR1BTKEGFRCMKLR1 | |
| SCHEMBL4030187 | 0.87 | ESR1 (0.61) | ESR1BTKEGFRCMKLR1 | |
| SCHEMBL4029342 | 0.86 | ESR1 (0.69) | ESR1BTKEGFRCMKLR1KMT2A | |
| SCHEMBL4027938 | 0.83 | ESR1 (0.61) | ESR1BTKEGFRCMKLR1 | |
| SCHEMBL4030858 | 0.82 | ESR1 (0.53) | ESR1BTKEGFRCMKLR1MERTK | |
| SCHEMBL27573495 | 0.81 | ESR1 (0.61) | ESR1BTKEGFRFAAHMERTK | |
| SCHEMBL4031188 | 0.81 | ESR1 (0.72) | ESR1BTKEGFRCMKLR1 | |
| SCHEMBL4025963 | 0.80 | ESR1 (0.71) | ESR1BTKEGFRCMKLR1KMT2A | |
| SCHEMBL4028914 | 0.79 | ESR1 (0.60) | ESR1BTKEGFRCMKLR1MERTK | |
| SCHEMBL27548054 | 0.78 | ESR1 (0.69) | ESR1BTKEGFRCMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | claimed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | claimed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | claimed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | claimed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | claimed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | claimed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | claimed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885BTK 896/4885EGFR 1874/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885BTK 810/4885EGFR 1662/4885 |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | ESR1 19/4885BTK 4213/4885EGFR 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.